rituximab
biogen,roche
['lymsm', 'rituximab']
r^2 is very effective in rituximab-refractory fl. asct demonstrates survival benefit in retrospective cohorts. pi3k inhibitors mostly pulled off market, but intermittent dosing strategies under investigation. don't forget about ezh2 inhibitors! #lymsm #asco22 
Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ??????